Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persistently low platelet counts
In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia (CIT) in more than half ...
23 hours ago
0
2





